×
About 5,868 results

ALLMedicine™ Vitiligo Center

Research & Reviews  1,887 results

Evidence of pyroptosis and ferroptosis extensively involved in autoimmune diseases at t...
https://doi.org/10.1186/s12967-022-03566-6
Journal of Translational Medicine; Zhang D, Li Y et. al.

Aug 13th, 2022 - Approximately 8-9% of the world's population is affected by autoimmune diseases, and yet the mechanism of autoimmunity trigger is largely understudied. Two unique cell death modalities, ferroptosis and pyroptosis, provide a new perspective on the ...

Assessing Treatment Delays for Vitiligo Patients: A Retrospective Chart Review.
https://doi.org/10.12788/cutis.0531
Cutis Patel K, Lopes FCPS et. al.

Aug 13th, 2022 - Many barriers to care exist for vitiligo patients that can impact patients' quality of life. Because early treatment of vitiligo is more efficacious, we investigated the factors associated with delay to treatment via a retrospective chart review o...

Association of rs4711998 of IL-17A, rs2275913 of IL-17A and rs763780 IL-17F gene polymo...
https://doi.org/10.1007/s00403-022-02382-8
Archives of Dermatological Research; Zapata-Salazar NA, Kubelis-Lopez DE et. al.

Aug 13th, 2022 - Vitiligo is the most common depigmenting disease characterized by achromic macules due to selective loss of melanocytes. The pathogenesis remains poorly elucidated, and multiple hypotheses exist regarding its pathogenesis. Evidence suggests that s...

Dermatologists share vitiligo breakthrough news with patients
https://www.mdedge.com/dermatology/article/257010/pigmentation-disorders/dermatologists-share-vitiligo-breakthrough-news
Marcia Frellick

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

Vitiligo-Like Depigmentation Induced by Anti-Programmed Death 1 Antibody.
https://doi.org/10.1097/DER.0000000000000932
Dermatitis : Contact, Atopic, Occupational, Drug; Zhang LW, Fu LX et. al.

Aug 12th, 2022 - Vitiligo-Like Depigmentation Induced by Anti-Programmed Death 1 Antibody.|2022|Zhang LW,Fu LX,Wang WJ,Lu YH,Chen T,|

see more →

Guidelines  1 results

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.

Aug 7th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  194 results

Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
https://clinicaltrials.gov/ct2/show/NCT05316987

Aug 10th, 2022 - Vitiligo is a T cell-mediated, autoimmune cutaneous disorder characterized by loss of functioning melanocytes from the basal layer of epidermis and/or hair follicles, leading to depigmented areas of the skin, mucous membranes, and/or hair (Strassn...

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04811131

Aug 8th, 2022 - This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment in subjects with non-segmental facial vitiligo.

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Aug 5th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment
https://clinicaltrials.gov/ct2/show/NCT04738149

Aug 5th, 2022 - The purpose of this research is to treat vitiligo with a topical PGF2α, microneedling and excimer laser. The goal is to have greater repigmentation than the standard of care (excimer) after 12 weeks of treatment. The study is a pilot, split study ...

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04927975

Aug 5th, 2022 - Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adve...

see more →

News  249 results

Dermatologists share vitiligo breakthrough news with patients
https://www.mdedge.com/dermatology/article/257010/pigmentation-disorders/dermatologists-share-vitiligo-breakthrough-news
Marcia Frellick

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

Prolonged Drug-Induced Hypersensitivity Syndrome/DRESS With Alopecia Areata and Autoimmune Thyroiditis
https://www.mdedge.com/fedprac/article/256980/mixed-topics/prolonged-drug-induced-hypersensitivity-syndrome/dress-alopecia
2LT Kathleen Krivda, USA, LTC John Campagna, MD, USA et. al.

Aug 11th, 2022 - Drug-induced hypersensitivity syndrome (DIHS), also called drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a potentially fatal drug-induced hypersensitivity reaction that is characterized by a cutaneous eruption, multior.

Dermatologists Share Vitiligo Breakthrough News With Patients
https://www.medscape.com/viewarticle/978705

Aug 5th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a US Food and Drug Administration (FDA)-approved, easy-to-use to...

Topical Ruxolitinib Quickly Relieves Atopic Dermatitis Itch in Black Patients
https://www.medscape.com/viewarticle/978653

Aug 4th, 2022 - Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream monotherapy over 8 weeks was associated with rapid and c...

FDA Approves Topical Ruxolitinib (Opzelura) for Nonsegmental Vitiligo
https://www.medscape.com/viewarticle/977464

Jul 19th, 2022 - The US Food and Drug Administration has approved topical ruxolitinib (Opzelura) for the treatment of nonsegmental vitiligo in patients aged 12 years or older, the manufacturer, Incyte, announced on July 18. The treatment, which was approved for tr...

see more →

Patient Education  8 results see all →